Viscosimetric affinity assay.

R Ehwald; R Ballerstädt; H Dautzenberg

doi:10.1006/abio.1996.0040

Home/Archive/PubMed

PubMed · 8742073

Viscosimetric affinity assay.

R Ehwald·R Ballerstädt·H Dautzenberg

View original source ↗Export metadata ↓

Abstract

Affinity ligands and/or affinity receptors may be quantified by a viscosimetric assay which can be carried out with a simple technique and has the potential of broad applications. The viscosimetric affinity assay is based on the high contribution of affinity bonds to the viscosity of an aqueous dispersion of a hydrocolloid that is bearing affinity ligands. In dispersions of such sensitive hydrocolloids at a concentration above the overlapping point, agglutination is not possible and the modulation of viscosity by the formation or dissociation of intercolloidal affinity bonds may be several orders of magnitude larger than the basic viscosity measurable in the absence of intercolloidal affinity bonds. If dispersions (30 g liter-1) of branched dextran with high molecular weight were used as reagent for concanavalin A (Con A), the Con A concentration necessary for a significant rise in viscosity was decreased with increasing colloid size. The viscosity of dispersions containing both a ligand-bearing high-molecular-weight dextran and an appropriate polyvalent receptor protein (lectin or antibody) showed a dependence on the concentration of free ligands (sugars or insulin) according to the law of mass action. In this competitive mode the viscosimetric affinity assay seems to be well adaptable to many analytical problems.

Explore related subjects

Antibodies Carbohydrates Chromatography, Affinity Colloids Concanavalin A Dextrans Indicators and Reagents Insulin Ligands Light Receptors, Cell Surface Scattering, Radiation Viscosity Comparative Study Journal Article Research Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

R Ehwald, R Ballerstädt, H Dautzenberg. 1996-02-01. Viscosimetric affinity assay.. https://doi.org/10.1006/abio.1996.0040

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2021

ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma.

In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted agents. By exploiting an integrated model based on patient-derived stem-like cells, faithfully recapitulating the original GBMs in vitro and in vivo, here, we identify a human GBM subset (∼9% of all GBMs) characterized by ERBB3 overexpression and nuclear accumulation. ERBB3 overexpression is driven by inheritable promoter methylation or post-transcriptional silencing of the oncosuppressor miR-205 and sustains the malignant phenotype. Overexpressed ERBB3 behaves as a specific signaling platform for fibroblast growth factor receptor (FGFR), driving PI3K/AKT/mTOR pathway hyperactivation, and overall metabolic upregulation. As a result, ERBB3 inhibition by specific antibodies is lethal for GBM stem-like cells and xenotransplants. These findings highlight a subset of patients eligible for ERBB3-targeted therapy.

Antibodies↗

PubMed2003

Isolation of antigens and antibodies by affinity chromatography.

Antibody-antigen binding constants are commonly strong enough for an effective affinity purification of antibodies (by immobilized antigens) or antigens (by immobilized antibodies) to work out a straightforward purification method. A drawback is that antibodies are large protein molecules and subject to denaturation under conditions required for the elution from the complex. Structures of antigens can vary but usually antigens are also equally subject to similar problems. The lability of the components can sometimes make the procedure sophisticated, but usually in all cases it is possible to find a satisfactory approach. In certain cases, specific interactions of the Fc part of antibodies are more facile to exploit for their purification.

Antibodies↗

PubMed2003

Longitudinal changes of anti-ganglioside antibodies before and after Guillain-Barré syndrome onset subsequent to Campylobacter jejuni enteritis.

Anti-ganglioside antibodies frequently are present in sera from patients with Guillain-Barré syndrome (GBS) during the acute phase, but no patients in whom anti-ganglioside antibodies were tested before the onset of the syndrome have been reported. We describe the first case of GBS subsequent to Campylobacter jejuni infection, in which longitudinal changes in anti-ganglioside antibody titers were measured before and after the onset of limb weakness. Serum antibody titers against GM1 (IgM/IgG), GM1b (IgM/IgG), GalNAc-GD1a (IgM/IgG), and GD1b (IgG) were highest on the day of onset, but negative before onset. Anti-C. jejuni IgG and IgA antibody titers paralleled those of the anti-ganglioside antibodies, indicative that C. jejuni infection triggered anti-ganglioside antibody production. Press et al. [J. Neurol. Sci. 190 (2001) 41] reported that anti-ganglioside antibody titers peaked during the recovery phase, but our findings are counter to theirs. We speculate that anti-ganglioside antibodies are the primary effectors of nerve damage in GBS.

Antibodies↗